Q4 EPS Estimates for Globus Medical Boosted by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Roth Capital upped their Q4 2025 earnings estimates for Globus Medical in a report issued on Monday, December 16th. Roth Capital analyst J. Wittes now forecasts that the medical device company will post earnings per share of $0.96 for the quarter, up from their prior forecast of $0.91. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share.

Globus Medical (NYSE:GMED) last announced its earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.18. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The business had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. During the same quarter last year, the business posted $0.57 earnings per share. The company’s quarterly revenue was up 63.1% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on GMED. Royal Bank of Canada lifted their price target on Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th. Bank of America boosted their price target on shares of Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a report on Wednesday, November 6th. BTIG Research boosted their target price on shares of Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Canaccord Genuity Group raised their target price on Globus Medical from $85.00 to $92.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, Stifel Nicolaus increased their price objective on Globus Medical from $80.00 to $92.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and an average price target of $94.55.

Globus Medical Stock Performance

Shares of NYSE GMED traded up $0.62 during trading on Thursday, hitting $82.40. The company had a trading volume of 87,639 shares, compared to its average volume of 991,150. The company has a market cap of $11.22 billion, a P/E ratio of 122.99, a PEG ratio of 1.99 and a beta of 1.19. The business’s 50-day moving average is $79.54 and its 200 day moving average is $73.17. Globus Medical has a 52 week low of $49.33 and a 52 week high of $87.22.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GMED. V Square Quantitative Management LLC acquired a new stake in Globus Medical during the 3rd quarter worth $27,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Globus Medical during the second quarter worth about $33,000. Quarry LP lifted its holdings in shares of Globus Medical by 698.4% during the 3rd quarter. Quarry LP now owns 495 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 433 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Globus Medical by 230.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock valued at $39,000 after purchasing an additional 385 shares during the period. Finally, International Assets Investment Management LLC bought a new stake in Globus Medical during the 2nd quarter worth approximately $52,000. Institutional investors own 95.16% of the company’s stock.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 30,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total value of $2,251,200.00. Following the transaction, the director now directly owns 536,275 shares in the company, valued at $40,242,076. This represents a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Daniel T. Scavilla sold 60,000 shares of Globus Medical stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total transaction of $4,801,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 97,500 shares of company stock worth $7,674,950. Insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.